Sponsor

CanCell Therapeutics

France 8 Rue Docteur Jean Francois Xavier Girod, 25000 Besançon, France

About the sponsor

CanCell Therapeutics focuses its clinical research on relapsed/refractory acute myeloid leukemia, with activity centered on patients whose disease has returned or has not responded adequately to prior treatment.

Acute myeloid leukemia
Relapsed disease
Refractory disease

The company’s research interest is directed toward treatment settings in which hematologic cancer control remains a major clinical need.

About Specializations

CanCell Therapeutics runs clinical trials in conditions such as Acute myeloid leukaemia refractory, Acute myeloid leukaemia recurrent, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

1 clinical trial

Acute myeloid leukaemia refractory+1

Not yet recruiting

Registered drugNo placebo

Study on CCTx-001, Cyclophosphamide Monohydrate, and Fludarabine Phosphate for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cctx-001
Sponsor:CanCell Therapeutics

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →